Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p 0.007 NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback